BAXTER/IMMUNO COMBO EXPANDS "OTHER" PLASMA, FACTOR IX, VACCINE PRODUCT OFFERINGS; MERGED FIRM HAS $1.6 BIL. IN SALES, 10% OF FRACTIONATION MARKET
Executive Summary
Baxter International's Aug. 28 definitive agreement to acquire the Austrian plasma fractionation products firm Immuno International will expand the Baxter product line to include Immuno's much larger "other" plasma product offerings, Factor IX and a line of vaccines.